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EXPLANATORY  MEMORANDUM 
Introduction:  Subject  and  scope of  the  proposal 
1.  Th~  aim o'  this  proposa•  for  a  Regulation  Is  to  Improve  the  protection 
of  !nnu\latlon  ln  the  pharmaceutical  sector.  In  this  respect,  It  forms 
part  of  Community  health  pol Icy,  which  seeks  to  create  the  conditions 
which  permi,  the  European  pharma~eutlcal  Industry,  by  the  turn  of  the 
ce~tury,  to  guarantee  theraupeutlc,  sciertlfiC,  economic  and  social 
progress  which  Is  Indissolubly  I Inked  with  the  discovery  and  use  of  ne~ 
medicinal  products. 
2.  Patents  st iII  represent  the  best  tool  for  protecting  innovation  1n  th  " 
respec.t.  There  is,  however,  the  risk.  that  this will  no  longer  be  u-,e 
case  if  an  appropr;ate  adaptation  to  evolving  needs  IS  not  duly  take~ 
into  account. 
!r-J~atlon  in  the  pharmaceutical  field  Is  particularly  threatened  in 
tr.is  respect. 
The  duration  of  patent  protectlo~  In  .E~rope  today  Is  generally  20  yea's 
from  the  date  on  wtl'.:;f;  the  paten!  app;tcat•O'".'  Is  filed.  Tnis  is  the 
d_rat"Jon  laic  OO'ftr,  1n  the  European  Pater-t  Convention  (Munich)  and  in  tne 
na: ional  laws  of  most  of  the  Member  States of  the  Community. 
Once  a  patent  has  been  granted,  the  patent  holder  may,  In  principle, 
Immediately  make  use  of  the  Invention  concerned on  the  mar~et.  Such  use 
may  even  be  made  before  the  patent  has  been  granted. 
However,  this  Is net  the  case  as  far  as medicinal  products  are 
concerned.  The  holder  of  a  patented medicinal  product  must  refrain 
from  uslng  It  until  he  has  obtained authorization  from  the  health 
authorities  to  place  the  product  on  the  market. - 4  -
Pr1or  author izatlon  procedures  for  medicinal  products  were  first 
introduced  In  the  Industrial lze~  ~~~tries  following  the  experience  w.·.· 
thalidomide.  Since  then,  the  public  authorities  have  required  the 
pharmaceutical  Industry  to  demonstrate  the  quality,  safety  and  efficac. 
of  new  medicinal  products.  These  prior  controls,  which  are  essential 
fer  the  protection of  pub! tc  health  and  which  are  beyond  question. 
involve  considerable  scientific and  technical  effort  and  expenditure. 
However,  It  should  be  pointed out  above  all  that  the  manifold 
(~~yslco-chemical,  biological  or  microbiological,  toxicological, 
pharmacological  and  clinical)  tests  required  to  compile  the  applicatlc~ 
which  w!  It  be  submitted  to  the  health  authorities  and  the  procedure 
Itself  for  obtaining  authorization  Involve  elapses  of  time  which  are 
becoming  Increasingly  longer  and  are  often  proportional  to  the 
Importance  of  the  innovation. 
This  leads  to  a  corresponding  loss  of  a  very  substantial  part  of  the 
ptr!od of  exclusivity granted  by  the  patent.  An  average  period  of 
12  years  between  the  discovery  of  a  new  medical  product,  at  which  time 
the  patent  application  is  filed,  and  Its  being  made  available  to 
patients  ls  currently  necessary,  the  effect  of  which  Is  to  reduce  the 
exclusive  exploitation  period  under  the  patent  to only  8  years. 
3.  Tn!~ situation,  which  has  com~ ab~ut  as  a  result  of  Interference  betwee-
t~J  types  of  administrative  procedure,  Imposes  heavy  penalties on 
pharmaceutical  research,  which  is  therefore  discriminated  against  as 
compared  with  other  technological  sectors. 
It  Is  true  that  thls  Interference also  takes  place  In  other  Industrial 
sectors,  In  particular  the  agro-chemlcal  sector,  the  food  sector,  etc .. 
but  It  Is  undisputed  that  the  pharmace.utJcaJ  sector  Is clearly  the  most 
affected.  It  Is  furthermore  the  only one  which,  for  many  years,  has 
been  asking  the  publ lc  authorities  to  find  a  solution. - 5  -
The  European  Federation of  the  Pharmaceutical  Industry  Associations 
put:llshed  In  1988  a  "Memorandum  on  the  Necessity  to  restore  the 
effect lve  duration of  patents  for  pharmaceutical  products'';  moreover. 
acditional  Industry  contributions  documenting  the  problem  of 
pnarmaceutlcal  product  patent  erosion  were  sent  to  the  Member  States  ·~ 
1989. 
In  1980,  the  Commission  took  the  view  that  It  was  necessary  to  protec~ 
irnovatlng  firms.  Directive  87/21/EEC  therefore  Introduced,  wltho~t 
prejuolce  to  patent  protection,  a  mechanism  which,  In  particular  for 
"high-technology"  medicinal  products,  prevents  a  second  appl !cant  for 
mark'.e.tl'1;  author::r.atron  from  presenting  a  smaller-scale  application  fc~ 
a  per I  o d  of  1  0  year s  from  t he  f ( r s t  author I  z a t I  on  for  market I  n  g  o  ~  t r <: 
product  In  the  CommunIty. 
The  Commission  takes  the  view  that  It  Is  time  to  protect  furthe:  ne ... 
medicinal  products,  but  that  it  would  be  premature  to  make  this  prop=s~ 
a  measure  of  general  appllcat ion  without  having  assessed  the  need  fv 
such  a  genera I 1  sed  measure  or  the  urgency  therefor. 
Nevertheless,  although  It  Is  confined  for  the  time  being  to  medicinal 
products,  the  Commission  does  not  exclude  the  possibl 1 lty 6f  a 
medium-term  adjustment  which,  while  extending  the  effects of  the 
proposal  to  other  ca1egories of  products,  might  provide  either  for  a 
similar  or  a  different  legal  mechanism,  In  I ight  of  the  circumstances 
and  the  experience  gained  in  the  pharmaceutical  sector. 
4.  Far  from  being  a  discriminatory  measure  In  favour  of  a  particular 
sector,  the  present  proposal  for  a  Regulation  alms  at  guaranteeing 
laboratories working  to  develop  new  medicinal  products  a  level  of 
protection equal  to  that  enJoyed  by  research  In  other  sectors. 
The  manifold  conseQuences  of  maintaining  the  status  ouo  are  reasons 
enough  to  have  convinced  the  Commission  of  the  need  to  try  to  find  a 
solutio·,  at  the  Community  level  adapted  to  the  particular  problem  anc 
taking  balanced  account  of  alI  the  legitimate  Interests  involved. 
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Part  One:  Broad  out I lne  of  the proposal  for  a  Regulation 
A.  Alms 
5.  ~ore  than  in  any  other  sector,  rese.:;:;:h  Is  particularly  v1tal  to  the 
pharmaceutical  Industry  Itself  and  to  society  as  a  whole.  There  Is  n~ 
subst ltute  for  Innovation  In  the  case of  medicinal  products. 
EL.:ropean  Industry  allocates between  10  and  15%  of  Its  turnover  for 
pharmaceutical  research  and  Is  virtually  self-financing.  It  Is  a 
hig~-rJsk activity  In  which  Investments  are  extremely  costly  and 
hazardous.  Out  of  a  total  of  about  10,000 substances  synthesized  by  a 
research  laboratory,  a  fe.,..  hundred  will  be  selected  for  the  fIling  c• 
pa~en~~.  out  of  whi(:"  only  one  to  three  wll I  actually  be  author !Zed  tc  :e 
pi~ced on  the  market. 
The  patent  protection  system  Is  therefore  essential  to  this  lnnovatin; 
sector,  in  that  Investment  In  research  Is  financed  by  mea'1s  of  reh:r~s 
obtained  during  a  period  of  exclusive  exploitation,  thereby  making  it 
POSSible  tO  ensure  tha!  self-funding  COntinues  and  to  guarantee  furt~e­
research  In  the  futuie. 
6.  Over  about  the  last  10  years  there  has  been  a  fall  1n  the  number  of 
molecules  of  European  origin  that  have  reached  the  research  and 
development  stage  \40%  as  against  65%  10  years  ago)  and  a  slow  erosic~ 
of  European  market  shares  as  compared  with  those  of  the  USA  and  Japa-. 
With  regard  to  the  latter,  It  should  be  noted  that,  apart  from  a 
general  context  which  Is  more  favourable  than  that  of  the  Community, 
notably  as  regards  social  security  systems,  price  levels  and  the 
relative size of  the  national  markets,  US  and  Japanese  companies  have, 
since  1984  and  1988  respectively,  benefitted  from  patent  term 
restoration  for  pharmaceutical  products  on  their  national  markets. - 7  -
7.  Tr-~e  Commission  Is  of  the  opinion  that  a  passive  att1tude  to  !he  curre~: 
sit~atlon will  ental!  two  types  of  risk  for  the  Community.  on  trle  c-." 
hand,  a  decrease  In  research  due  to  Insufficient  resources  an::.  or'''"' 
c'.~.er  hand:  the  relocation  of  research  centres  away  to  non-me:::.er 
countries  that  offer  better  protection  and  an  environment  mo~e  caner_~  ,e 
t :J  I n nov at I  on . 
Furthermore,  the  existence  among  the  ~ember States  of  the  Commun1ty  o: 
several  pa:  I iamenta~y  lnltlat ives,  of  which  one  Is  at  a  very  advances 
procedural  stage,  providing  for  supplementary  protection  for  patente: 
medicinal  product  leads  to  the  necessity  to  harmonise  national 
developments  at  the  Community  level. 
3.  T:t·  basic  ObJectives of  this  proposal  for  a  Regulation  therefore  con:e···, 
the  requlre~~~:s relating  to  the  proper  functioning  of  the  internal 
market,  lmprove~ent cf  our  competitiveness  as  compared  with  that  of  o~r 
trade  partners  and  the  encouragement  of  research  and  development  in  t~e 
health  field. 
8.  Details  and  c~aracteristlcs of  the  proposed  system 
(a)  Details 
9.  The  proposal  for  a  Regulation  provides  for  the  creation of  a  protect tor: 
certificate su•  cr~ne~ 1s  1n  the  fo:m  of  a  supplementary  protection 
certificate. 
This  certificate will  be  granted  by  the  patent  office  tn  each  Member 
State at  the  request  of  the  holder  of  a  (national  or  European)  "basic" 
patent  relating  to a  product  authorized  to  be  marketed  In  the  State 
concerned. 
The  same  medicinal  product  that  Is  patented  and  authorized  to  be 
marketed  In  several  Member  States may  therefore  be  the  subject  of  as 
many  national  certificates,  the  conditions  for  obtaining  which,  the 
basic  detal Is  and  the  duration of  protection  betng  laid  down  unifor~'Y 
for  the  entire Community  territory. 1  • 
.  I  • 
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The  certificate  confers  the  same  protection  as  the  basic  patent,  but 
only  protects  the  product  covered  by  the  authorlzat ion,  for  al 1 
pharmaceut leal  uses  author lzed,  unt II  the  expiry  of  the  basic  patent. 
The  certificate  Is  I inked  to  both  the  marketing authorizations  system 
and  the  patents  system  In  such  a  way  that  It  becomes  void  in  particular 
If  the  authorlzat ion  Is  not  val ld  or  If  the  basic  patent  Is  revoked. 
(b)  Characteristics 
-A balanced  system 
1he  proposa:  for  a  Regulation  as  a  whole  constitutes  a  balanced  sys~e­
since  each  of  Its  essential  featu.res  has  been  determined  in  the  11gh: 
of  the  alms  of  the  proposal  and  the  interests  Involved.  The 
Commission  takes  the  view  that  the  proposed  system  should  be  effect1~e 
and  appropriate  for  the  industry's  reQuirements  without  neglecting 
other  substantial  aspects of  national  and  Community  health  pol icy. 
The  proposal  for  a  Regulatio~ therefore  concerns  only  new 
medicinal  products.  It  does  not  Involve  granting  a  certificate  for  a: 
medicinal  products  that  are  author !zed  to  be  placed on  the  market. 
Only  one  certJficate may  be  granted  for  any  one  produ=t.  a  product 
being  understood  to  mean  an  active  s~bstance  In  the  strict  sense. 
Minor  changes  to  the medicinal  product  such  as  a  new  dose,  the  use  cf 
a  different  salt  or  ester  or  a  different  pharmaceutical  form  wi  I I  not 
lead  to  the  issue  of  a  new  certificate. 
12.  However,  the  proposal  Is  not  con.flned  to  new  products only.  A new 
process  for  obtaining  the  product  or  a  new  application  of  the  prod~:t 
may  also  be  protected  by  a  certificate.  All  research,  whatever  the 
~trategy or  final  result,  must  be  given  sufficient  protection. 
13.  The  certificate does  not  protect  the  ~xplred patent  In  Its entirety. 
It  protects only  the  product  authorized  to  be  placed  on  the  market. 
Furthermore,  account  is  taken  of  the  process  of  development  of  the 
product ·for  the  purpose  of  obtaining  the  authorization  in  such  a  way 
tnat  the  protection  afforded  to  the  product  Is  i Inked  to  the  uses  fc" 
treatment  which  were  authorized  during  the  life  of  the  patent. - 9  -
14.  The  duration of  the  protection  given  by  the  certificate  Is  set  In  sue" 
a  way  as  to  enable  It  to  afford  actual  overall  protection  similar  tc 
that  In  other  sectors of  technology.  This  period  Is  set  at  16  years 
In  the  proposal.  However,  It  Is  set  as  a  function  of  the  first 
market lng  authorization  In  the  Community,  which  means  a  loss  to 
Industry  In  ccuntr les  In  which  the  authorization  Is  granted  much 
! a ter. 
Moreover,  the  duration of  the  protection given  by  the  certificate  ffia 1 
not  under  any  circumstances  exceed  10  years.  The  purpose  of  this  IS 
to  set  a  cut-off  point  to  penal tze  against  authorizations obtained  ct 
a  very  1 ate  date  (more  than  15  years  after  the  f i I 1 ng  of  the  patent) 
and  to  compensate  in  some  way  for  the  lack  of  supervision  of  the 
undertaking's  dl I tgence  as  regards  the  management  of  the  health 
dossier. 
15.  The  proposal  provides  for  a  trar.s1tionat  arrangement  to  take  acco~~~ 
of  the  fact  that  the  problem  of  the  erosion  of  patents  In  the 
pharmaceutical  field exists at  present  for  medicinal  products  wh1C~ 
ha~e already  been  placed  on  the  market  and  that  it  would  be  I 1  tog1ca~ 
to  disregard such  products  completely  at  the  time  when  a  solution  ts 
adopted.  Furthermore,  there  Is  the  danger  that  a  gap  will  develop 
between  the  expiration of  some  major  pharmaceutical  patents  and  the 
discovery  of  products  developed  from  new  technologies  which  could 
jeopa~dise the  cycle of  self-financing  research  If  medicinal  prod~c~s 
concerned  were  not  able  to  benefit  from  being  granted  a  certificate. 
Lastly,  It  Is  to  be  hoped  that  the  European  pharmaceutical  Industry 
wl  l l  be  able  to close some  of  the  gap  which  has  arisen  between  itself 
and  Its maJor  competitors  In  the  International  market.  In  the  USA, 
the  waxman-Hatch  Act  entered  Into  force  In  September  1984.  In  Japan. 
the  revision of  the  Patents  Law  took  effect  on  1  January  1988. 
- A simple,  transparent  system - 10  -
16.  The  proposal  for  a  Regulation  provides  for  a  simple,  transparent 
syste~ which  can east ly  be  applied  by  the  parties  concerned. 
It  therefore  does  not  lead  to excessive  bureaucracy.  There  Is  no  nee~ 
for  any  new  administrative  body  and  the  patents offices  should  be  at:e 
to  Implement  the  procedure  for  granting  the  certificate without  an 
excessive  burden  being  placed  on  their  administrations. 
The  documents  required  to  file  an  appl icatlon  for  a  certificate are 
1  lml  ted  to  what  Is  str Ietty  necessary  to  enable  the offices  to  take  a 
decision  on  granting  the  certificate or  to  reject  the  appl teat ion. 
:xamlnatton of  the  conditions  to  be  fulfilled  for  the  certificate  to 
be  granted  Involves  the  use  of  objective  data  that  are  easy  to  verify. 
However,  coordlnat ion  with  the  health  authorities  could  be  provided 
for  by  the  Member  States  If  they  consider  this  to  be  necessary. 
The  adoption  of  a  standard  system  to  calculate  the  duration  of  the 
~rotection given  by  the certificate without  abstraction  of  certain 
Information specific  to  the  case  (date of  granting  the  authorization. 
date  of  fIling  the  patent  appttcat ton,  date  of  expiry  of  the  patent:' 
means  that  the  calculation  Js  easy  to  make. 
The  procedure  envisaged  last /y  gua-antees  the  transparency  of  the 
system  since  the  decision  to  grant  the  certificate and  the  appl icat ,c~. 
are  both  published,  the  latter  having  been  filed  sufficiently early 
after  marketing  author Jzatl(.m  was  given  to  enable  third partie!;  tot-: 
s~lftly  Informed. 
c.  Need  for  and  scope of  a  Community  solution 
12.  In  view  of  the  problem of  tne  erosion of  patents  In  the  pharmaceutica 
sector,  a  genuine  Europea~ market  cannot  accommodate  ex  novo  nationa: 
solutions  that  might  affect  the  free movement  of  medicinal  products 
and  the  competition  rules within  the  Community. - 11  -
A Community  solution ental I lng  harmonization  of  the  conditions  for  t~~ 
appl lcatlon of  the  system  Introduced  and  the  rules  governing  It  anc 
standardization of  the  duration of  protection of  medicinal  products 
therefore  has  to  be  found  to  secure  the  establ lshment  and  proper 
functioning  of  the  Internal  market. 
19.  However,  with  regard  to patents,  the  national  laws  cannot  be 
approximated  without  also  preserving  harmonization  between  the 
national  systems  and  the  European  patent  system.  It  specifically  ra<O 
~o  be  avoided  that.  within  one  and  the  same  Member  State,  new 
meoicinal  products  enjoy  an  overall  period  of  protection  that  dlffe·s 
accordIng  to  whether  the  patent  was  granted  under  the  nat lena I  I  aws  cr 
under  the  European  Patent  Convention  to  which,  on  1  January  1990, 
there  were  14  contracting States,  of  which  10  are  In  the  Community 
~with  the  exceptions  of  Ireland  and  Portugal)  and  four  are  States c' 
the  European  Free  Trade  Area  (Switzerland,  Austria,  Sweden  and 
:...iechtenstein). 
This  logical  need  for  harmonization  at  two  levels  could  theoretical ·j 
be  met  If  a  Community  Directive  app! icable  only  to medicinal  produc~~ 
protected  by  a  national  patent  were  accompanied  by  a  partial  revis1c~ 
of  the  European  Paten1  Convent ion  to  provide  similar  protect ion  for 
medicinal  products  protected by  a  r~ropean patent. 
Howe~er,  it wou:d  not  seem  to  be  possible  to  provide  in  the  short  te·~ 
for  the  revision of  the  European  Patent  Convention or  for  such  a 
revision  to  be  adopted  unless  this  Is  done  by  the  Member  States  act .~g 
unanimously,  since Article  172(a)  of  the  Convention  provides  that 
States which  do  not  ratify or  accede  to  a  revised  text  of  the 
Convention shall  cease  to  be  parties to  lt. 
These  facts  have  prODipted  the  CommIssIon  to  seek  to  fInd  a  Communi  t ·y 
solution  appl 1can1e  to •11  medicinal  products  author lzed  to  be  place8 
on  t~e  m~rket  and  protected  by  a  patent  In  their  territory whatever 
path- national  or  European- has  been  followed  for  that  purpose. - 12  -
20.  The  proposed  system  takes  the  legal  form  of  a  new  protection 
certificate,  sui  generls,  which  Is  national  ·1n  character  and  lies  at 
the  Interface  between  two  systems,  that  of  prior  authorizations  for 
the  placing  on  the  market  of  medicinal  products  and  that  of  their 
protection by  patent,  and  which  confers  on  the  system  Its  specific 
characteristics and  special  nature. 
These  can  be  seen  first  of  all  In  the  scope of  the  certificate  and  the 
conditions  for  obtaining  lt.  The~  can  also  be  seen  In  the  subject  of 
the  protection,  which  Is  limited  both  by  the  authorization  Itself 
since  the  protection extends only  to  the  authorized  product  and  only 
for  the  therapeutic uses of  it which  were  the  subject  of  an 
authorization,  and  in  the  claims  of  the  basic  patent. 
They  can  also  be  seen  in  the  fact  that  the  non-val ldity  of  both  the 
authorization  and  the  patent  render  the  certificate vola. 
The  certificate  Is  therefore  a  national  document  harmonized  at  the 
Community  level  and  l,s  essentially different  from  the  basic  patent. 
Furthermore,  It  may  not  under  any  circumstances  distort  the  operatic~ 
of  the  European  patent  system.  The  result  would  be  completely 
~;fferent  if  It  were  possible  to obtain  a  certificate only  for 
medicinal  products  protected  by  a  national  patent. 
21.  ~fortiori, when  use  is  made  of  the  European  procedure  to obtain  a 
Community  patent,  It  will  liKewise  be  necessary  that  the  certificate 
can  apply  equally  to medicinal  products  protected  by  a  Community 
patent.  The  proposal  has  been  developed with  a  view  to  applying 
equally  to  such  an  eventual lty,  with  minor  modifications,  If 
necessary. - 13  -
t  sr.ould,  lastly,  be  pointed  out  that,  as  part  of  the  ::;ve~a!i  r:--:::.--, 
,,f  ai lgnment  between  the  EEC  and  the  EFTA  which  may  resut:  i:'  ~  ...  :::c 
Furopean  economic  area,  the  Commission  has  taken  care,  since  a 
~c~si~le Community  solution  to  the  erosion  of  pharmaceutical  pate~:~ 
was  flr~t mooted,  to  Inform  the  EFTA  Member  States  and  to  involve  t:c-
':.Joint  de!:beratlons. 
~J.  A  Comrr.~nlty  solution  Is  justified  by  the  fact  that  any  measure 
affecting  health  must  be  considered  In  an  appropriate  context. 
appropriate,  the  Community  Institutions will  hold  political 
u  scussions  on  measures  that  form  part  of  Community  health  policy. 
With  rega~d t0  the  ~ealth field,  the  CommiSSion  Is  aware  that 
objections  to  this  proposal  for  a  D•rectlve  will  be  expressed.  Fer 
from  ignoring  the  arguments  of  those  concerned,  the  Commission  has 
taken  account  of  them  In  Its  proposal. 
2~.  The  argument  concerning  health  and  social  security costs  is  no  do~t~ 
the  most  important.  Health  expenditure  Is  rising  continuously 
throughout  the  world.  At  the  same  time,  the  shortfalls  in  the  sociz:' 
security  systems  are  a  subject  of  concern  to  those  with  political 
responsibilities.  It  Is  therefore  legitimate  to  Question  the  poss1c:'= 
effects of  this  proposal  for  a  Regulation  on  costs. 
7ne  system  established  by  the  proposal  does  not  apply  to  al 1  patente: 
medicinal  products  placed  on  the  market,  but  only  to  those  which 
consist  In  new  medicinal  products ..  A  large  proportion  of  the 
medicinal  products  sold on  the  market  have  only  few  Innovative 
features,  or  none  at alI.  These  are  not  covered  by  the  scope  of  the 
proposal.  Each  year,  only  about  50  new  medicinal  products  are 
authorized worldwide,  It  Is  these  that  are  covered  by  the  proposal 
for  a  Directive.  As  for  the  transitional  arrangement  provided  for  in 
the  proposal.  the  aim or  this  Is  to  strike  a  fair  balance  between  what 
Industry  needs  and  what  can  reasonably  be  accepted  by  society. - 14  -
Furthermore,  the  proposal  for  a  Regulation  does  not  affect  the  Member 
States·  ability  to  control  the  prices  of  medicinal  products  on  the;r 
markets. 
Lastly,  the  present  proposal,  moreover,  favours  a  possible  fall  In  P.e 
~rices of  the  medicinal  products  covered  by  this  proposal  In  1 tght  of 
tne  extens\on o1  tne period  for  recuperation of  Investments. 
Another  argu~ent  concerns  the  effect  of  the  proposal  on  the  access  o~ 
generic  products  to  tne marKet  and  therefore  o~  competition  within  t~~ 
Community  between  research  based  Industry  and  producers  of  generic 
products. 
it  Is  tr;Je  that  the  longer  the exclusivity  period,  the  longer  the 
delay  before  generics  enter  the  market.  The  aim  of  the  proposal  is 
speciflcal ly  to ensure  that  researct··  based  Industry  has  a  market 
exclu; :vity  of  sufficJent  !e!"'!:;~~  t:·  perm1t  recovery  of  their 
;nvestments. 
However,  thIs will  not  mean  any  reduct ion  In  competition.  The  we: 1 
know~ effect  of  the  patents  system  Is  to  promote  competition  throu~~ 
Innovation.  For  this,  a  balance  is  strucK  between  the  encourageme~t 
of  Innovation  and  the  making  of  lnnovatlor.s  available  to  society  by 
disclosing  them.  Generic  products exist  only  If  new  medicinal 
p~cd~cts are  developed  and  disclose.  Producers  of  generic  products 
therefore  have  ever1  tnterest  In  net  seeing  research  belng  stifled. 
Furthermore,  the  Commission  would  point  out  that,  to  reach  the  market 
place,  generic  products  must  meet  the  same  Quality,  safety  and 
efficacy criteria as  are  reQuired  for  new  medicinal  products  If  it  is 
wished  to  maintain  pub! lc  health  In  Europe. 
In  devising  the  proposal,  the  Commission  has  taken  care  to  strike  a 
balance  between  the  interests of  researchers  and  those  of  generic 
firms,  notably  In  laying  down  the  duration of  the  protection  given ti 
~he certificate and  the  transitional  arrangements. - 15  -
26.  In  conclusion,  the  debate  on  the  patentabl I lty  of  medicinal  products 
has  already  taken  place  In  all  of  the  Member  States  and  everyone  has 
endorsed  an  alternative of  effective protection  for  research.  This 
has  helped  to  put  Europe  In  the  forefront  as  far  as  the  Qual lty  of 
~ubi lc  health  Is  concerned.  It  Is  now  a  question  of  making  coheren~ 
use  of  the options  that  Europe  has  chosen. 
D.  Lega:  basis 
27.  The  introduction  of  a  different  period of  protection  for  medicinal 
products  in  each  of  the  Member  States of  the  Community  would  create 
obstacles  to  their  free  movement  within  the  Internal  market  and 
distort  the  conditions  of  competition. 
The  Introduction  of  a  standard,  adeQuate  period of  protection  for  the 
results of  pharmaceutical  research,  on  the  other  hand,  wi  11  be  sure  t= 
encourage  Innovation  and  technical  progress  at  Community  level  and  to 
promote  lntra-Commun1ty  trade  In  medicinal  products. 
The  Commission  proposes  to  take  Article  100a  of  the  EEC  Treaty  as  th~ 
legal  basts  for  this  proposal. 
In  drafting  the  proposal,  the  Commission  has  taken  due  account  of  the 
provisions of  Art1cie  Sc  of  the Treaty  and  has  found  that  there  is  nc 
need  to  prc~ide for  special  or  exceptional  provisions  for  the  time 
being. 
Similarly,  the  Commission  has  considered  the  Question of  the  high 
level  of  protection  required  In  the  field of  health,  safety, 
environmental  protection  and  consumer  protection  under  Article  100a(3· 
of  the  Treaty.  It  has  taken  ful I  account  of  these  aspects  In  the 
proposal. - 16  -
Part  Two:  Examination of  the  provisions 
Article  1 
28.  The  concept  of  a  medicinal  product  as  used  In  everyday  speech  is  more 
difficult  to define  In  legal  terms. 
Furthermore,  since  the objectives of  the  patent  system  are  differer.t 
from  those  of  the  system of  marketing  author izatlon,  the  definition c' 
a  medIc Ina 1  product  In  pharmaceut I  ca I  I  aw  cannot  be  taken  to  be 
exactly  the  same  as  that  In  patent  law. 
What  Is  author lzed  to  be  placed  on  the  market  is  referred  to  as  a 
"proprietary  medicinal  product",  I.e.  "any  ready-prepared  medicinal 
product  placed on  the  market  under  a  special  name  and  in  a  special 
pack"  (Article  1.1  of  Directive  65/65/EEC). 
However,  it  may  be  the  medicinal  product  that  is  patented,  meaning  tre 
active  Ingredient,  the  process  by  which  the  medicinal  product  Is 
obtained,  or  an  appl lcatlon or  use  of  the  medicinal  product. 
For  the  purposes  of  the  certificate.  which  lies  at  the  interface of 
the  two  systems,  the  terms  "product"  has  been  chosen  as  a  common 
denominator.  The  exact  meaning  given  to  It  is  defined  in  Article  1. 
which  Is  baseo  on  the  definitiOn of  a  medicinal  product  laid  down 
Directive  65/65/EEC.  However,  the  qual lfier  "active"  is  added  to  the 
term  "substance"  In  order  to  Include  the  concept  of  an  "active 
ingredient  or  ~active substance"  used  In  patent  law. 
Consequently,  the  term  "product"  Is  not  understood  to mean  a 
proprietary  med1clna1  product  or  a  medicinal  product  In  the  wider 
sense,  but  In  the  narrower  sense  of  product  used  ln  patent  law  which, 
when  appl led  to  the  chemical  and  pharmaceutical  field,  means  the 
active  Ingredient. - 17  -
2g.  The  purpose of  the  expression  "product  protected  by  a  patent"  Is  to 





The  proposal  does  not  provide  for  any  exclusions.  In  other  words,  a: 1 
pharmaceutical  research,  provided  that  It  leads  to  a  new  Invent ton 
that  can  be  patented,  whether  It  concerns  a  new  product,  a  new  process 
for  obtaining  a  new  or  known  product,  a  new  application of  a  new  or 
known  product  or  a  new  comblnatlon  of  substances  containing  a  new  or 
known  product,  must  be  encouraged,  without  any  discrimination,  and 
must  be  able  to  be  given  a  supplementary  certificate of  protection 
pro~lded that  all  of  the  conditions  go~ernlng the  appl !cation of  the 
prooosal  for  a  Reg~!ation are  fulfl I led. 
Article  2 
This  Article  dete~r.,ines  the  scope  of  the  proposal.  It  refers  to  any 
product  that  Is  the  subJect  of  both  a  system  of  protection  by  pate~t 
and  a  system of  administrative authorization prior  to  Its  being  place~ 
en  the  market.  It  Is  specified  that  the  authorization  concerned  is 
that  provided  for  In  Directives  65/65/EEC  and  81/85/EEC,  thereby 
~ak!ng  It  clear  that  the  proposal  appl les  only  to  medicinal  products 
for  human  or  veterinary  use.  On  the  o~her  hand,  the  text  does  net 
state under  what  kind  o1  law  patent  protection  Is  given  and  It  follc,.s 
from  this  that  the  proposal  applies  to all  pharmaceutical  products 
protected  by  patent  In  at I  of  the  ~ember States,  whether  this  be  a 
national  patent,  a  European  patent  or,  In  due  course,  a  Community 
patent.  Lastly,  mention  Is  made  of  the  legal  Instrument  used  to 
resolve  the  problem  at  hand. - 18  -
31.  Only  patented  products  a . ..;  c:··..,~~1.  whatever  the  legal  source  of  the 
patent.  With  a  view  to  the  single  market,  the  national  patent  laws 
must  not  be  harmonized  without  harmonlzat ion  also  being  mainta,ned 
-
between  the  national  patent  systems  and  the  European  system.  In  t~e 
present  case  ,  It  Is  a  quest Jon  of  prevent lng  the  pharmaceutical 
Industry  from  being  faced  with  the  Illogical  situation  whereby,  in  o:--.-: 
and  the  same  ~ember State,  a  new  medicinal  product  may  or  may  not 
benefl t  from  the  appl icatlon  of  the  Regulation  depending  on  whether 
the  corresponding  patent  was  obtained  nationally  or  at  the  Europea~ 
I  eve I. 
~he  two-level  harmonization  reQuired,  In  addition  to  which  there  Is  ,:--. 
t~is specific  instance  a  certain urgency  in  view  1n  part lcular  of  the 
iead  gained  by  the  US  and  Japanese  legal  systems  and,  moreover,  the 
constantly  increasing  periods  required  to obtain authorizations  to 
place  products  on  the  market,  cal Is  for  the  adoption of  a  legal 
solution  that  maintains  such  harmonization  and  enables  it  to  be 
Implemented  simply  and  swiftly.  For  this  purpose,  the  proposal  for  3 
Regulation  proposes  the  creation of  a  protection certificate 
sui  generls,  this  being  a  supplementary  protection certificate.  the 
conditions  and  the  rules  for  obtaining  which  are  laid  down  in  a 
uniform  mann~r  for  a!l  of  the  Member  States of  the  Community. 
Article  3. 
ihis Article  lays  down  the  basic conditions  to  be  met  by  a  product  ir. 
order  to obtain  a  certificate.  As  the  certificate  Is  a  national 
document,  compl lance  with  these  conditions must  be  examined  with 
respect  to  the  Member  State  In  which  the certificate appl icatlon  Is 
submitted  and  to  the  appl lcatlon date. 
33.  First,  It  has  to  be  verified whether  the  product  Is  protected  by  a 
patent  In  force.  It  Is  this patent  that  serves  as  the  basis  for  the 
certificate  for  the  purposes  of  the  proposal  for  a  Regulation. - 19  -
It  may  oe  that  the  ~reduct  Is  protected  by  several  patents,  e.g.  bi  a 
patent  for  a  product  ~nd a  patent  for  the  procedure  used  to  obta1~  t·~ 
voduct.  In  this case,  it  Is  for  the  holder  of  the  patents  concecr:e:: 
to  chose  one  of  them  as  the  basic  patent.  This  choice  Is  particular·. 
important  If  the  subject  and  the  content  of  the  protection granted tr 
t~e certificate  are  respectively  I lmlted  by  the  subject  and  content  c• 
the  basic  patent. 
34.  The  product  must  have  obtained  a  valid marketing  authorization  In 
accordance  with  Directive  65/65/EEC  or  Directive  81/851/EEC,  depend1~; 
on  whether  it  Is  a  medicinal  product  for  human  use  or  a  veter lnary 
medicinal  product.  More  speclflcal ly,  what  Is  authorized  to  be  plact~ 
or:  the  market  Is  what  Directive  65/65/EEC  refers  to  as  a  propr ietac;.-
medicinal  product,  i.e.  "any  ready-prepared  medicinal  product  placec:: 
en  the  market  under  a  special  name  and  In  a  special  pack",  !n 
accordance  with  the  definition given  In  Article  1  of  that  Directive 
The  product  therefore  meets  this  second  condition  if  the  propr1etar; 
rned1cinal  product  containing  It  has  been  granted  the  authorizatio~ 
co:;cerned. 
35.  it  occurs  very  often  that  one  and  the  same  product  Is  successful ry 
granted  several  authorizations  to  be  placed  on  the  market,  namely  eac~ 
time  a  modification  Is  made  affecting  the  pharmaceutical  form,  dose, 
composition,  indications,  etc.  In  such  a  case,  only  the  first 
authorization  for  the  product  to  be  placed  on  the  market  In  the  ~e~be~ 
State  In  which  the  applIcation  Is  presented  Is  taken  Into  account  for 
the  purposes  of  the  proposal  for  a  Regulation,  In  particular  for 
calculating  the  period of  six  months  which  the  holder  of  the  basic 
patent  has  to  submit  an  application  for  a  certificate.  Furthermore, 
If  the  first  authorization given  Is  also  the  first  authorization  to 
place  the  product  on  the  market  tn  the  Community,  It  serves  as  the 
only  reference  for  al t  of  the  Member  States  for  the  purposes  of 
calculating  tne  duration of  each of  the  certificates granted  In  each 
of  the  Wember  States  for  the  same  product  (see  Article 8). - 20  -
36.  Lastly,  the  product  must  not  h_.w  been  the  subJect  of  a  certificate  ir 
the  Member  State  concerned.  The  certificate  Is  designed  to  enco~rage 
research  Into  new  medicinal  products  so  that  the  durat lon  of 
~rotectlon  It  affords,  together  with  the  effective  duration  of 
protection  by  patent,  Is  sufficient  to enable  the  investments  made  i~ 
the  research  to  be  recovered.  However,  It  would  not  be  acceptable.  1n 
view  of  the  balance  reQuired  between  the  Interests  concerned,  for  th,s 
total  duration of  protection for  one  and  the  same  medicinal  product  t8 
be  exceeded.  This  might  nevertheless  be  the  case  if  one  and  the  sa~~ 
product  were  able  to  be  the  subject  of  several  successive 
certificates. 
This  calls  for  a  strict  definition of  the  product  within  the  mean~~~ 
of  Article  2.  If  a  certificate  has  already  been  granted  for  the 
active  Ingredient  Itself,  a  new  certificate may  not  be  granted  for  ere 
and  the  same  active  ingredient  whatever  minor  changes  may  have  beer. 
made  regarding  other  features  of  the  medicinal  product  (use  of  a 
different  salt,  different  exciplents,  different  pharmaceutical 
presentation,  etc.). 
In  conclusion,  It  should  be  noted  that,  although  one  and  the  same 
product  may  be  the  subject  of  several  patents  and  se~eral 
authori2aticns  to  be  placed on  the  market  in  one  and  the  same  Mem~er 
State,  the  supplemen:ary  protection certificate wi  I I  only  be  granted 
for  that  product  on  the  bas1s of  a  single patent  and  a  single 
authorizatior.  to  be  placed  on  the  market,  namely  the  first 
chronologically given  In  the  State  concerned  (the  first  authorizaticn 
In  the  Community  being  taken only  to calculate  a  uniform  duration  of 
different  certificates  for  one  and  the  same  product). 
37.  Lastly,  Article  3  specifies that  the  certificate  Is  granted  to  the 
holder  of  the  basic  patent.  Any  decision as  to  the  advisabl llty of 
applying  for  a  certificate must  be  left  to  the  holder  of  the  basic 
patent  who  alone  Is  able  to decide  whether  this  Is  advisable. - 21  -
Article  4 
3?  7~e  supplementary  protection certificate  Is  a  protection  certificate 
o:ui  generis  Inasmuch  as  It  Is  linked  to  both  an  authorization  to  pl;::::e 
the  product  on  the  market  (the  first  chronologically given  In  the 
State  concerned)  and  to  a  previous  patent  (the basic patent).  This  ic 
already  evident  from  the  conditions  for  obtaining  the certificate, 
which  require  both  that  the  baste  patent  Is  In  force  and  that  the 
a:.Jthorlzation  Is  valid,  falling  which  the  certificate  Is  void. 
30  ·  The  delimitation  of  the  subJect  protected  by  the  certificate  also 
Illustrates  this  duality  since  the  protection  given  by  the  certlfica~e 
Is  I lmlted  in  two  ways. 
tt  Is  thus  often  the  case  In  the  chemical  and  pharmaceutical  field 
~ha!  a  paten~ protects  a  series of  products  based  on  the  same  formula. 
However,  on: y  SC:",-:;  of  the'2?  products  w  I I I  subsequent I  y  be  deve toped 
a~d possibly  only  one  may  be  put  on  the  market.  In  such  a  case.  the 
certificate  wl  t 1  or:~ protect  the  product  covered  by  the  author1zat1c~ 
and  not  all  of  the  products  r;:rotected  by  the  patent. 
At  the  same  t lme,  the  product  author !zed  wi  II  Itself  be  1 imited  by  tr.e 
subject  protected  by  the  baste  patent.  If  the  basic  patent  protects  a 
compound  x,  where  the  product  author lze~ consists of  a  combination  of 
compound  x  ana  anott'"ter  active  Ingredient  only  compound  x  wi  r I  be 
protected  by  the  certificate. 
Furthermore,  the  certificate wl  I I  protect  only  the  product  covered  by 
the  authorization,  namely  the  product  within  the  strict meaning  of 
Article  2. 
40.  Lastly,  the  fact  that  the  certificate  Is  based  on  both  the  basic 
patent  and  the  authorization  can  also  be  seen  In  the  link  between  the 
protection given  and  the  use.of  the  product.1 
In  the  French  text,· the  term  "uti II sat I  on"  Is  used  for  both  the  pater-.t 
system  and  the  author I zat ton  system,  the  terms  1  n  French  norma I I y  be  1 ~; 
"application"  and  "indication"  respectively.  In  the  English  text,  the 
same  term  "uses''  is  used  for  both  systems. - 22  -
In  this  respect,  a  new  product  patent  normally  gives  the  product 
absolute protection  so  that  any  use  of  the  patented  product,  even  fer 
non-patented  applications,  constitutes  an-Infringement,  I.e.  It 
protects  at 1  possible uses  that  the  product  may  have. 
The  certificate does  not  given  such  protection.  On  the  one  hand,  the 
1 ink  with  the  author lzatlon  system means  protection of  the  product 
covered  by  the  first  authorization,  whl  le  I imitlng  It  to  the  uses  o• 
the  product  successively  authorized  prior  to  the  expiry  of  the  basic 
patent  (research  laboratories  freQuently  develop  new  uses  of  the  same 
product,  which  are  the  subject  of  new  marketing  authorizations).  The 
marketing  authorization  is  actually  given  several  years  after  the 
~;Jtng of  the  patent,  during  which  time  the  medicinal  product 
undergoes  multiple  tests  for  one  or  more  very  specific uses.  In  v:e~ 
of  this,  it  would  seem  to  be  logical  to  protect  it,  by  means  of  the 
certificate,  for  al 1  uses which  have  been  the  subject  of 
authorizat1011s. 
~1  Furthermore,  only  uses  in  the  pharmaceutical  field  as  defined  in 
Directive  65/65/EEC  and  81/851/EEC  come  under  the  protection  of  the 
certificate  (authorized  use  of  the  product  as  a  herbicide,  for 
example,  would  not  be  protected  under  the  certificate). 
t2.  On  the  other  hand,  tne  pro~~ctlon granted  by  the  certificate  Is 
limited  by  that  of  the  basic  patent.  In  the  case  of  a  product  pate::~. 
the  limitation  under  the  patent  wi  II  not  apply  since  this  type  of 
:-atent  protects all  possible  uses  of  the  product.  However,  In  the 
case  of  an  appf icatlon  patent,  the  certificate wl  r I  only  be  abie  to 
protect  the  use or  uses  claimed  In  the  patent,  provided  that  they  we·e 
authorized  prior  to  the  etplry of  the  basic patent. 
Article  5 
43.  The  effects of  the  certificate on  the  subject  to which  It  refers  as 
described  In  Article  4  are  the  same  as  those of  the  basic  patent. - 23  -
The  patent  system  has  hitherto constituted  the  best  tool  to  encourage 
research.  It  Is  therefore  not  surprising,  In  view  of  the  objective  of 
this  Regulation,  that  the  certificate grants  the  same  rights,  subJect 
to  tne  same  1 Imitations. 
44.  C~nsequentty,  In  the  case of  a  basic  patent  covering  a  product,  the 
r tghts granted  by  the  certificate will  be  the  same  as  those  granted tt 
the  patent,  but  I lmtted  to  any  use  of  the  product  authorized  prior  to 
the  expiry  of  the  patent. 
Similarly,  In  the  case  of  a  baste  patent  covering  a  use  of  the 
product,  the  right  granted  by  the  certificate wt  1 I  be  the  same  as 
those  granted  by  the  patent,  but  limited  to  the  use  covered  by  the 
patent  and  authorized  prior  to  the  expiry  of  the  patent. 
Lastly,  In  the  case  of  a  baste  patent  covering  a  process  for  obtaini~~ 
the  product.  the  rights granted  by  the  certificate  wl I 1  be  the  same  as 
tno~e granted  by  the  patent,  but  I lmlted  to  the  procedure  used  to 
obtain  the  authorized  product.  The  rights  granted  by  the  certificate 
will  be  extended  to  the  product  If  the  taw  applicable  to  the  bas:c 
product  lays  down  that  the  protection of  a  process  for  obtaining  a 
product  extends  to  the  product  directly  obtained  by  that  process . 
.:5.  The  certificate  Js  lastly  subject  to  the  same  restrictions  as  the 
baste  patent.  Restrictions on  prf~ate acts  for  non-commercial 
~urposes,  restrictions on  acts  for  experimental  purposes  relating  to 
~he subject  of  the certificate and  restrictions on  obligatory  licences 
relating  to  the  subject  of  the  certificate  are  some  of  the  possible 
restrictions on  the  rights granted  by  the  certificate  If  these  are 
also  Included  in  the  basic patent. 
Article 6 
46.  ThJs Article  concerns  the  time  during  which  the  appl !cation  for  the 
certificate must  be  submitted  and  the  content  of  the  appl !cation. - 24  -
With  regard  to  the  time,  a  period of  six  months  Is  provided  from  the 
date  on  which  the  first  authorization  to  place  the  product  on  the 
market  In  the  State  concerned  was  obtained.  This  solution  takes 
particular  account  of  the  Interests  Involved;  those of  the  patent 
holder  who,  after  having  applied  for  the  certificate,  may,  If  he  so 
wishes,  forego  the  certificate  If  h!s  product  proves  to  be 
unsuccessful  on  the  market;  and  those of  third parties  who  have  everi 
Interest  In  knowing  as  early  as  possible  whether  or  not  the  product 
concerned  wl  I I  be  protected  by  a  certificate once  the  basic  patent  h!s 
expired. 
r:u.rthermore,  It  need  not  be  feared  that  applications  for  a  certificate 
wl !\be routlnely  and  sys~e~atical ly  filed  each  time  authorization  to 
place  a  product  on  the  market  Is  given,  since  the  conditions  laid  d=ft~ 
In  Article  3  for  obtaining  the  certificate are strict  and  allow  onl_, 
one  certificate per  product  corresponding  to  the  first  authorization 
giver  In  th~  State  concerned. 
A?.  It  may  happen  that  authorization  is  given  before  the  basic  patent  is 
granted,  In  particular  In  the  field  of  genetic  engineering  in  which 
appllcat Ions  may  be  left  pending  for  quite  a  long  t lme.  In  such 
cases,  the  period  begins  on  the  date  on  which  the  patent  Is  give~. 
4c.  The  follow·Jng  comments  should  be  made  with  regard  to  the  content  of 
the  application.  Few  documents  are  required.  Apart  from  the  request 
1tself,  a  copy  of  the  first  authorization  to  place  the  product  on  t~e 
market  In  the  State  concerned  Is  required  as  this enables  the  produc: 
to  be  Identified.  If  this  authorization  ls  not  also  the  first 
authorization  to  place  the  product  on  the  Community  market,  a  cop)  of 
the  latter  also  has  to be  attached  since  the  duration of  the 
certificate wl  11  be  calculated,  In  al r  Member  States  In  which  a 
certtf,cate  Is  applied  for,  by  reference  to  this criterion alone. 
Information  enabl lng  the  basic  patent  to  be  Identified must  also  be 
'":·ov I ded. - 25  -
The  author lty  empowered  to grant  the  certificate wl  I I  have  to  verify 
that  the  authorlzation(s)  and  the  patent  refer  to  one  and  the  same 
~coduct. 
Lastly,  the  appl lcatlon  must  contain  a  summary  of  the  pharmacologica: 
properties of  the product.  These  are  the  properties  which  enable  it 
to  be  characterized  as  a  medicinal  product  and,  conseQuently,  which 
help  to  provide  a  better  description of  the  product  as  a  medicinal 
product.  It  Is  also  a  reQuirement  that  Is  easy  to  meet  once  all  the 
experiments  on  the  product  hav~ been  carried out. 
Article  7 
~0.  The  application  for  a  certificate must  be  submitted  to  the  patent 
offices of  the  Member  States.  The  office  responsible  for  each 
application  for  a  certificate  is  that  In  the  State which  has  delivere:: 
or  on  whose  behalf  was  del lvered  a  basic  patent  and  in  which  the  firs: 
authorization  for  that  State was  obtained. 
For  one  and  the  same  medicinal  product  patented  and  authorized  tote 
placed on  the  market  In  several  ~ember States,  as  many  applications 
for  certificates must  be  submitted  to  the  corresponding  patents 
offices. 
The  appl lcatlon  for  a  certificate may  be  subject  to  the  payment  of  a 
tax  to  the  patents office concerned  to  cover  expenditure  Incurred  1n 
deal lng  with  the  application. 
The  appllcatlol\  for  a  certificate must  lastly  be  published  by  the 
patents office.  This  Is  to ensure  that  thlr~ parties are  Informed  as 
soon  as  possible. 
Article 8 
SO.  The  duration  of  protection granted  by  the  certificate  is established 
on  the  basis of  s~veral  factors. ,. 
- 26  -
First,  the  duration  must  be  sufficiently  long  to  meet  the  objectives 
of  the  proposal.  In  this  respect,  It  Is  necessary  to  avoid 
dlscr lminating  against  pharmaceutical  research  and  therefore  to 
subject  It  to  conditions  similar  to  those  which  would  obtain  if  the 
medicinal  products  were  not  subject  to  prior  author izat 10n  to  be 
olaced  on  the  market. 
The  duration of  the  certificate covering  one  and  the  same  medicinal 
product  must  be  the  same  throughout  the  Community  In  order  to 
facl 1 I tate  the  functioning  of  a  genuine  Community  market. 
Account  also  has  to  be  taken  of  the  laws  benefitting  competitive  f1r~~ 
In  their  own  markets  In  order  to  put  all  of  European  Industry  on  a 
s i m  II a r  foot I  n  g . 
However,  It  Is  also  essential  to  take  account  of  other  aims  of  hea~~­
pol icy  and  therefore  to  prevent  the  duration  of  protect ion  of  the 
medicinal  products  from  becoming  a  barr ler  to  the~. 
Lastly,  the  system  must  be  kept  simple,  while  allowing  for  a  certe:-~ 
degree  of  balance  between  all  of  the  interests  Involved. 
Tne  Commissicn  there1ore  proposes  to calculate  the  duration  of  the 
protection of  the  certificate on  the  basis  of  the  protection  perioc 
"lost"  under  the  patent,  i.e.  the  period  between  the  date  on  which  t"e 
patent  application  is  filed  and  the  date  on  which  the  first 
authorization  to  place  the  product  on  the  market  in  the  Community  1s 
obtained. 
As  the  author lzatlcn  dates  for  one  and  the  same  medicinal  product 
differ  from  one  ~ember  State  to  another,  the  later  an  authorization  1s 
given  In  a  Member  State,  the  shorter  the  period  of  effective 
protection  wl  I 1  be  there.  The  Commission's  pol Icy  on  author lzat Ions 
should  nevertheless  reduce  the  gaps  between  ~ember  States  and 
therefore virtually  level  out  the  effective durations  of  protectior 
afforded  to  medicinal  products. - 27  -
To  put  medicinal  products  on  a  footing  simi tar  to  that  which  would 
obtain  In  the  absence  of  authorization  means  placing  them  on  the  ter~s 
that  obtain  In  other  sectors of  technology  not  subJect  to 
authorization.  The  Commission  puts  the  average  period  from  the  date  o~ 
which  the  patent  appl !cation  Is  fl led  to  the  date  on  which  It  Is 
placed  on  the  market  at  four  years.  The  duration  of  protection  under 
the  certificate  thus  calculated  (the  period  "lostM  less  four  years) 
takes  effect  on  the  day  following  the  end  of  the  lawful  term  of  the 
basic  patent. 
52.  It  should  be  stressed  that,  If  the  effective  period  remaining  under 
the  basic  patent,  I .e.  from  obtaining  the  authorization  to  the  end  of 
the  patent,  Is  added  to  the  duration of  protection  under  the 
certificate- the  period  lost  less  four  years- a  total  effective 
per lod  of  protect !on  for  the  medicinal  product  concerned  of  sixteen 
years  Is  obtained,  below  which,  In  the  Commission's  view,  the 
objectives of  this  proposal  for  a  Regulation  wi  I 1 not  be  attained. 
53.  Lastly,  It  should  be  pointed  out  that  the  proposal  also  provides  for  a 
final  date  after  which  the  medicinal  product  enters  the  publ lc  domai~. 
The  duration of  the  certificate may  not  exceed  10  years  from  the  date 
on  which  It  takes  effect. 
The  slmpl lclty of  the  syste~ we2ns  that  It  Is  not  possible  to  take 
account  of  certain  factors,  such  as  the  di 1 igence  that  the  Innovating 
firm  has  shown  throughout  alI  the  tests  required  to  obtain  the 
authorization.  The  proposal  compensates  for  this shortcoming  by 
restricting the  certificate  In  cases  In  which  authorization  was 
obtained  very  late.  For  example,  If  the  authorization was  obtained 
eighteen  years  after  the  appJJcatlon  for  the  corresponding  patent  was 
filed,  the  duration of  the certificate  Is  not  fourteen  years  (elghtee~ 
minus  four)  but  ten  years,  after  which  there  Is  no  further  protection. - 28  -
Article  9 
54.  This  Article  refers  to  the  conditions  governing  the  grant  of  the 
certificate or  rejection of  the  application  and  publication. 
The  only  particular  comment  cal fed  for  Is  to  underscore  the  simp! icity 
of  the  procedure;  no  particular  difficulties should  arise  In  Its 
application. 
AI  1  patent offices must  In  particular  be  able  to  verify  the  condit1ons 
referred  to  In  Article  3  under  which  the  certificate  Is  obtained. 
Contacts  may,  If  necessary,  be  provided  for  between  the  patent  office 
and  the  authority  responsible  for  authorizing  the  product  to  be  pla:e: 
on  the  market,  if  this  Is  considered  necessary  for  the  purposes  of  t~e 
procedure. 
A.r  t  i c I e  10 
55.  This  Article  states  that  the  ~ember States  may  provide  that  renewa~  of 
the  certificate will  be  subject  to  the  payment  of  a  fee.  It  will  be 
for  the  ~ember  States  to  establIsh  the  amount  If  they  decide  to 
introduce  such  fees,  fa I lure  of  which  to  pay  would  cause  the 
ce r  t if  ; cat e  t c  r  a;:."::><.· 
Article  11 
5~.  The  proposal  for  a  Regulation  lays  down  three  grounds  for  nul I ity  of 
tne  certificate. 
1)  The  certificate  Is  void  If  the  conditions  for  obtaining  the 
certificate as  laid  down  In  Article  3  have  not  been  compl  led 
IIIIth.  This  will  In  particular  concern  cases  In  which  the 
authorization  to  place  the  product  on  the  marlcet  was  not  valid - 29  -
or  was  not  the  first  l.n  the  Member  State  concerned,  cases  In 
which  the  baste  patent  was  no  longer  In  force  when  the 
certificate was  appl led  for  and,  last ty,  cases  In  which  one  and 
the  same  product  was  the  subject  of  several  certificates  In  the 
same  Member  State,  In  which  case  only  the  certificate granted  :n 
respect  of  the  first  authorization  to  place  the  product  on  the 
market  tn  the  State  concerned  wl  I I  be  valid. 
2)  The  certificate  Is  void  If  the  baste  patent  Is  not  val ld  when 
Its  lawful  term  expires.  Where  renewal  of  a  patent  until  Its 
term  expires  Is  Indicative of  the  value  of  the  product  It 
protects,  this  ground  for  nul 1 tty  wt  I I  play  an  Important 
selective  role. 
Furthermore,  the  exclusive  protection granted  by  the  certificate 
over  a  given  period  Is  not  lawful  unless  the  product  concerne: 
meets  not  only  the  specific conditions  for  obtaining  the 
certificate  {Article  3),  but  also  the  criteria of  patentability 
for  grant  of  the  basic  patent. 
It  Is  therefore  necessary  to  specify  that  the  certificate  is 
void  If  the  basic patent  or  at  least  that  part  of  the  baste 
patent  that  corresponds  to  the  product  covered  by  the 
certificate  has  been  revoked.  It  Is  therefore  necessary  to 
specify  expressly  that  an  application  for  revocation  of  the 
~· 
basic patent,  with  a  view  to  the  revocation  of  the  certificate, 
may  be  submitted  even  after  the  lawful  term  of  the  baste  patent 
has  expired. 
3)  The  certificate  Is  also  void  If  the  subject  that  It  protects  is 
not  covered  by  the  basic  patent.  The  aim  Is  to prevent  a  given 
product  not  protected by  a  patent  from  enjoying  the exclusive 
protection of  a  certificate without  having  fulfl 1  ted  the 
conditions  and  obligations  spec·lflc  to  the  patent  system. - 30  -
This  ground  for  nul I lty  Is  therefore  based  on  the  same  principle  as 
the  prevIous  ground.  It  remaIns  to  be  poInted out  that,  1  f  the 
subject  of  the  certificate  Is  only  partially covered  by  the  basic 
patent,  the  declaration of  nul 1 ity  of  the  certificate may  take  the 
form  of  a  corresponding  I Imitation of  the  certificate,  this  being  in 
accordance  with  the  principle of  proportional lty. 
57.  Lastly,  the  Article specifies  that  any  person  may  request  a 
declaration of  nullity of  the  certificate  from  the  authority  which 
granted  It,  I.e.  the  relevant  patent office.  The  decision of  the 
office  wl  I I  be  subject  to appeal,  as  provided  for  In  Article  12. 
Article  12 
~8.  This  Article  provides  that  a  decision  to  reject  an  application  and  a"':· 
decision of  a  patent  office  to  which  an  appl !cation  for  a  certificate 
was  made  to  annul  the certificate are  open  to  the  same  appeals  as 
provided  for  in  national  law  against  similar  decisions  regarding 
patents.  This  Is  an  essential  legal  guarantee,  claims  under  which  are 
subject  to  national  patent  law  of  the  State  In  which  the  certificate 
was  granted. 
:::.  The  same  posslbi llty of  ap~eal  shall  apply  to  decisions  in  respect  c-f 
the  grant  of  a  certificate,  for  reasons  of  Invalidity of  the  grantin] 
decision,  for  example,  a  defective  procedure,  lack  of  competence  of 
the  granting  authority,  etc.  The  certificate  Itself  may  Indeed  be 
annulled  under  the  provisions of  Article  11,  and  the  annulment  ltseif 
is  open  to  appeal  under  the  provisions of  Article  12. 
Article  13 
60.  The  aim  of  this Article  Is  to  lay  down  transitional  arrangements,  a 
part tcularly  Important  and  sensitive  part  of  the  proposal.  The 
Commission  takes  the  view  that  certain criteria have  to  be  complied 
with  In  order  to  arrive  at  an  appropriate  solution. - 31  -
A balancing  of  al 1  the  Interests  at  stake  Is  fundamental  to  achieve  c~ 
acceptable  solution.  In  this  respect,  the  aim  Is  neither  to  cover  al  1 
products  already  being  marketed  nor  to  exclude  them  totally. 
The  proposed  solution must  avoid  any  distortion  to  the  system  for 
g~antlng authorization  to  place  a  product  on  the  market  that  might  ca~se 
f,rms  to  delay  submitting  an  appl !cation  for  such  authorization. 
Lastly,  the  solution must  be  free  of  uncertainty  In  order  to  enable 
c~mpanles to  plan  ahead. 
61.  In  the  !!ght  of  these  criteria,  the  Commission  proposes: 
(a)  to  apply  the  proposal  for  a  Regulation  to  alI  products  protected 
by  a  patent  In  force  which  have  not  yet  received  authorization 
to  be  placed  on  the  market; 
(b)  to  apply  It  also  to  all  products  authorized  after  1  January  198~ 
and  the  patents  for  which  expire  after  1  July  1992. 
Laying  down  specific dates  avoids  the  uncertainty  caused  by  any 
reference  to  the  date  of  entry  Into  force  of  the  proposal.  W1t~ 
regard  to  the  choice of  dates,  authorization  since 
1  January  1984  should enable  European  industry  to  close  the  gap 
between  them  and  their  US  competitors,  who  have  had  restoration 
of  pharmaceutical  patents  since  1984.  Furthermore,  by  setting  a 
patent  expiry  date  of  post  1  January  1992,  a  product  for  which  a 
patent  was  f! led  In  1972  wl  I I  not  be  able  to  be  granted  a 
certificate unless  the  corresponding  authorization was  given 
more  than  twelve  years after  It  was  f! led  (after  1984), 
I.e.  after  a  period  represent1ng  the  average  reference  period  in 
the  proposal  for  a  Directive,  which  was  calculated on  the  basis 
of  existing statistics. 
c)  to  limit  the  maximum  duration  of  protection  given  by  a  certificate 
to  five  years  for  products  authorized  since  1984.  This  Is  a 
reduction  to  half  of  the  normal  time  provided  for  In  the  proposal. No L  114/10  OUicial Journal ot the  European Communities  8.  5. 90 
Proposal  for  a  Council  Regulation  (EEC)  concerning  the  creation  of  a  supplementary 
protection certificate for medicinal products 
(COM(90)  101 final- SYN 255) 
(Submitted by the  Commission  on  3 April 1990) 
(90/C 114/11) 
THE  COUNCIL OF THE  EUROPEAN  COMMUNITIES, 
Having regard to  the Treaty establishing  the  European 
Economic  Community,  and  in  particular  Article  1  OOa 
thereof, 
Having  regard  to  the  proposal  from  the  Commission, 
In  cooperation with  the  European Parliament, 
Having  regard  to  the  opinion  of  the  Economic  and 
Social  Committee, 
Whereas pharmaceutical research plays  a decisive  role in 
the continuing improvement in  public health; 
Whereas medicinal products that are the result of long, 
costly research will  not continue to be  developed  in  the 
Community  and  in  Europe  unless  they  are  covered  by 
favourable  rules  that provide for sufficient  protection to 
encourage such research; 
Whereas at the moment the period that elapses  between 
the discovery of a new medicinal product, at which time 
the  application  for a  corresponding  patent is  filed,  and 
authorization  to  place  the  medicinal  product  on  the 
market  is  continually  increasing,  thereby  making  the 
period  of effective  protection  under  the  patent  insuf-
ficient to cover the investment put into the research; 
Whereas this lack of protection penalizes pharmaceutical 
research; 
Whereas  the  current  situation  is  creating  the  risk  of 
European  research  centres  relocating  to  countries  that 
already offer greater protection; 
Whereas  a  uniform  solution  at Community level  should 
be  provided  for,  thereby  preventing  the  heterogeneous 
development  of  national  laws  leading  to  further 
disparities  which  would  be  likely  to create  obstacles  to 
the  free  movement  of  medicinal  products  within  the 
Community and thus directly to  affect the establishment 
and the functioning of the  internal  market; 
Whereas  the  creation  of  a  supplementary  protection 
certificate  granted,  under the  same  conditions,  by each 
of the  Member States  at the  request of the  holder of a 
national  or  European  patent  relating  to  a·  medicinal 
product  for  which  valid  marketing  authorization  has 
been  granted  by  the  State  concerned  is  necessary; 
whereas the legislative  form  of a  Regulation is  therefore 
the  most appropriate; 
Whereas the  duration  of the  protection  granted  by  the 
new  certificate  should  be  determined  to  enable  a 
medicinal product to  be  given  the effective  protection it 
would have  if it  were  not subject to  authorization to be 
placed  on  the  market;  whereas,  for  this  purpose,  the 
holder of both a patent and a  certificate  should be  able 
to  enjoy  16  years  of  exclusivity  from  the  time  the 
product is  first placed on the market in  the Community; 
Whereas  all  the  interests  at  stake,  including  those  of 
public health, in  a sector as  complex and sensitive as  the 
pharmaceutical  sector  must  nevertheless  be  taken  into 
account; whereas, for this purpose, the certificate cannot 
be  granted for a period exceeding 10  years; whereas the 
protection  granted  should  furthermore  be  strictly 
confined. to the product covered by  the marketing auth-
orization; 
Whereas a fair balance should also be struck with regard 
to  the  determination  of  the  transitional  arrangements; 
whereas  such  arrangements .  should  enable  the 
Community pharmaceutical industry to catch up to some 
extent with  its  main  competitors  who,  for  a  number of 
years, have been covered by  laws  assuring them of more 
adequate  protection,  while  making  sure  that  the 
arrangements  do  not  compromise  the  achievement  of 
other legitimate objectives concerning the health policies 
pursued at both national  and Community level, 
HAS ADOPTED THIS REGULATION: 
Article  1 
Definitions 
For the purposes of this  Regulation, 
(a)  Product  means  any  active  substance  or combination 
of  substances  presented  for  treating  or  preventing 
disease  in  human  beings  or animals  and  any  active 
substance  or combination  of substances  which  may 
be  administered  to  human  beings  or animals  with  a 
view  to  making  a medical  diagnosis or to  resto:ing, 
correcting  or  modifying  physiological  functions  in 
humans or in  animals; 8. 5.90  Official Journal of the European Communities  No C 114/11 
(b)  Product protected by  a patent means  any  product as 
defined  in  (a)  protected  by  a  patent  covering  the 
product itself, or a process to obtain the product, or 
an  application  of the  product or a  combination  of 
substances containing the product; 




Any product protected by  a  patent in  the  territory of a 
Member State and subject,  prior to being placed on the 
market,  to  an  administrative  authorization procedure as 
laid  down  in  Council  Directive  65/65/EEC (')  or 
Council Directive 811851/EEC (')  may,  under the terms 
and  conditions  provided  for  in  this  Regulation,  be  the 
subject of a certificate. 
Article 3 
Conditions for obtaining a certificate 
1.  A  certificate  shall  be  granted  if,  in  the  Member 
State in  which the application  referred to  in  Article 6 is 
submitted and at the date of that application, 
(a)  the  product is  protected by a  patent in  force,  here-
inafter called basic patent; 
(b)  a  valid  authorization  to  place  the  product  on  the 
market  has  been  granted  in  accordance  with 
Directive  65/65/EEC or Directive  811851/EEC, as 
appropriate; 
(c)  the  product  has  not  already  been  the  subject  of a 
certificate; 
(d)  the authorization referred to in  (b)  is  the first  auth-
orization to place the product on the market. 
2.  The certificate shall be granted to the holder of the 
basic patent. 
Article 4 
Subject matter of protection 
Within the limit of the protection conferred by the basic 
patent,  the  protection  conferred  by  a  certificate  shall 
extend only to the product covered by the authorization 
to place it on the market and for any authorized use  of 
the product before the expiry of the basic patent and  as 
provided for in  Directives  65/65/EEC or 81/851 /EEC. 
(')  OJ No 22, 9.  2.  1965,  p.  369/65. 
(')  OJ No L 317, 6.  11.  1981,  p.  1. 
Article 5 
Effects  of the certificate 
Subject to the provisions of Article 4, the certificate shall 
confer the  same  rights  as  conferred  by  the  basic  patent 
and shall  be subject to the same  limitations. 
Article 6 
Application for a  certificate 
1.  The  application  for  a  certificate  shall  be  lodged 
within six months of the date on which the authorization 
to place the product on the market referred to in Article 
3 (1)  (b)  was  granted. 
2.  Notwithstanding  the  proviSion  of  paragraph  1, 
where  the  authorization  to  place  the  product  on  the 
market is  granted before the basic patent is  granted, the 
application  for  a  certificate  shall  be  lodged  within  SIX 
months of the date on which the patent is  granted. 
3.  The application for a certificate shall contain: 
(a)  a request for the grant of a certificate; 
(b)  a copy of the authorization to place  the  product on 
the  market,  as  referred  to  in  Article  3  (1)  (b),  in 
which the product is identified; 
(c)  if the authorization referred to in  (b)  is  not t:1e  first 
authorization for placing the product on the market 
in  the  Community,  information  regarding  the  date 
on  which  the  first  such  authorization  was  granted, 
the identity of the product thus authorized, the legal 
provision  under which  the  authorization  procedure 
took place and a copy of the authorization; 
(d)  identification of the basic patent; 
(e)  information  regarding  the  pharmocological  prop-
erties  of the  product  in  the form  of a  summary  as 
provided  for  in  particular  in  Article  4a  (4)  of 
Directive 65/65/EEC. 
Article  7 
Lodging of an application for a certificate 
1.  The  application  for  a  certificate  shall  be  lodged 
with the central industrial property office of the Member 
State which granted the basic patent or on whose behalf 
it  was  granted  and  in  which  authorization  to  place  the 
product on the market as  referred to in  Article 3 (1)  (b) 
was  obtained. 
2.  Member States may require that the  application for 
a certificate shall be subject to payment of a fee  imposed 
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3.  The application for a  certificate shall be  published 
by the authority referred to in  paragraph 1. 
Article 8 
Duration of the certificate 
1.  The  certificate  shall  take  effect  on  the  day 
following the end of the lawful term of the basic patent 
for a  period equal to the period which elapsed between 
the date on which the application for a basic patent was 
lodged  and the  date  of the first  authorization to  place 
the product on the market in the Community, as  referred 
to in Article 6  (3) (c), reduced by a period of four years. 
2.  Notwithstanding paragraph  1,  the  duration  of the 
certificate  may  not exceed  10  years  from  the  date  on 
which it takes effect. 
Article  9 
Grant of the  certificate  or rejection  of the  application 
1.  The  authority  referred  to  in  Article  7  (1)  shall 
reject the application for a certificate if the application or 
the  product  to  which  it  relates  does  not  meet  the 
conditions laid down in  this  Regulation. 
2.  Where  the  application  for  a  certificate  and  the 
product to which it relates meet the conditions laid down 
in  this  Regulation, the authority referred to in  Article  7 
(1)  shall  grant the certificate. 
3.  The fact that a certificate has been granted shall be 
published  by  the  authority referred  to in  Article  7  (1), 
giving in  particular the following details: 
(a)  name and address of the holder of the certificate; 
(b)  number of the basic patent; 
(c)  identity of the product covered by the certificate; 
(d)  duration of the certificate; 
(e)  a  summary  of  the  pharmacological  properties  as 
referred to in Article 6 (3) (e). 
Article  10 
Renewal fees 
1.  Member States may require that the certificate shall 
be subject to the payment of renewal fees  imposed by the 
authority referred to in  Article 7  (1). 
2.  The failure to pay such fees  will  result in  the lapse 
of the certificate. 
Article 11 
Grounds for nullity of the certificate 
1.  The certificate shall be void if: 
(a)  it was granted contrary to the provisions of Article 3; 
(b)  the basic patent is  no longer in  force when its lawful 
term expires; 
(c)  the subject of the certificate is  not covered by a basic 
patent. 
2.  For the purposes of paragraph 1 (b), an application 
for a  declaration  of nullity  of the  basic  patent may  be 
presented  before  the  lawful  term  of the  patent expires. 
3.  In  the  case  referred  to  in  paragraph  1  (c),  if the 
subject of the certificate  is  only partially covered by the 
basic patent, the declaration of nullity shall take the form 
of a  corresponding limitation of the certificate. 
4.  Any person may request a declaration of nullity of 
the certificate from  the authority which granted it. 
Article  12 
..·~  ··:leals 
The decisions of the auth  ·:referred to in  Article 7 (1) 
taken under Articles  9  \  ad  11  shall  be  open to the 
same  appeals  as  those  ; . ~.vided  for  in  national  law 
against  similar  decisions  taken  in  respect  of  national 
patents. 
The  same  shall  apply  in  respect  of  decisions  taken 
pursuant to Article 9 (2)  which are alleged to be invalid 
on grounds  other than  those  referred  to  in  Article  11. 
TRANSITIONAL PROVISION 
Article  13 
1.  Any  product  which,  on  the  date  on  which  this 
Regulation  enters  into  force,  is  protected  by  a  valid 
patent and  for  which  authorization  to  place  it  on  the 
market in the Community has not yet been obtained may 
benefit from the application of this  Regulation. 
2.  Any  product  which,  on  the  date  on  which  this 
Regulation  enters  into  force,  is  protected  by  a  valid 
patent which expires  after 1 July 1992  and for which  a 
first  authorization  to  place  it  on  the  market  in  the 
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be granted a certificate, the duration of which may not, 
however, exceed five  years. 
3.  An  application  for  a  certificate,  made  under 
paragraph 2, shall be submitted within six months of the 
date on which this  Regulation enters into force. 
FINAL PROVISIONS 
Article  14 
Implementing  Regulation 
1.  Detailed  rules  for  the  application  of  this  Regu-
lation, in so far as  they are necessary, shall be laid down 
by an implementing Regulation. 
2.  The implementing  Regulation  shall  be  adopted by 
the Commission. 
Articles  15 
Entry into force 
This  Regulation shall  enter into  force  60  days  after  its 
publication  in  the  Official  Journal  of the  European 
Communities. 
This  Regulation  shall  be  binding  in  its  entirety  and 
directly applicable  in  all  Member States. ..  5&-
v. 
FICHE  D'IMPACT  SUR  LA  COMPETITIVITE  ET  L'EMPLOI 
1.  Quelle est  Ia  Justification prlnclpale de  Ia  mesure? 
-Promotion de  Ia  recherche  pharmaceutiQue. 
- Amel  ioratlon  de  Ia  protection de  Ia  sante pubiiQue. 
- Renforcement  de  Ia  competltlvlt6 de  l'lndustrte europeenne  sur  le 
marche  mondlal. 
-Bon fonctlonnement  du  marche  lnterleur. 
11.  Caract6rlst1Ques des entreprlses concern6es. 
La  proposition concerne  des  flrmes  pharmaceutiQues. 
Vu  le  coQt  eleva  du  developpement  des  nouveaux  prodults,  les  flrmes 
pharmaceutiQues  sont  souvent  de  grandes entreprlses  (multlnatlonales 
ou  natlonalesl.  I I  exlste  neanmolns  uncertain nombre  de  petites et 
moyennes  entreprlses A vocation  natlonale,  Qui  fo~t egalement  de  Ia 
recherche,  notamment  dans  le  domalne  de  Ia  blotechnologie,  ou  11  n'est 
pas  toujours necessalre de  disposer  de  grands  moyens. 
111.  Quelles sont  les obligations  lmposees  dlrectement  aux  entreprlses? 
Se  conformer  a  Ia  procedure  prevue  pour  !'obtention d'un certlficat 
complementalre  de  protection. 
IV.  Quelfes sont  les obligations susceptlbles d'&tre  lmposees 
lndlrectement  aux  entreprlses via  les autorltes  locates  7 
Aucune. 
v.  Y a-t-11  des mesures  sp6clales pour  les PME  7 
Non. .. 
·-~.o:.. 
VI.  Quel  est  l'effet pr6vlslble 
a)  sur  Ia  comp6tltlvlt6 des  entreprlses ? 
Un  des  objectlfs poursulvls  par  Ia  mesure  concern6e  est  preclsement 
de  renforcer  Ia  comp6tltlvlt6 des entreprlses europ6ennes  face  A 
leurs concurrents 6trangers  (USA),  Japon). 
b)  sur  l'emplol  ? 
Le  renforcement  de  Ia  competltlvlte devralt  se  tradulre  par  un 
effet  plutot  posltlf sur  l'emplol. 
VII.  Les  partenalres soclaux ont-lls 6t6 consultes sur cette proposition? 
ont  ete consultees 
- les  associations de  l'lndustrle pharmaceutlque  et  chimique, 
- les  associations  de  consommateurs, 
- les  chambres  de  commerce  et  d' Industria. VI. 
FICHE  FINANCIER£ 
La  presente  proposition n'a pas  d'effet  sur  le  budget  communautalre.  El  le 
sera menee!  bien grace  aux  ressources exlstantes a  Ia  DG  111. 